Current options to manage Waldenström’s macroglobulinemia

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenström’s Macroglobulinemia. Blood. 2006;107:3442–3446.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenström’s macroglobulinemia. Ann Oncol. 2006;17:488–494.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;118:3052–3056.
   Web of Science ®Google Scholar
• Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenström’s macroglobulinemia incidence: a large population-based study. Cancer. 2012;118(15):3793–3800.
   PubMed Web of Science ®Google Scholar
• Vijay A, Gertz MA. Waldenström’s macroglobulinemia. Blood. 2007;109:5096–5103.
   PubMed Web of Science ®Google Scholar
• Dimopoulus MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström’s macroglobulinemia (WM) and related disorder: IWWM-7 consensus. Blood. 2014;124:1404–1409.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenström’s macroglobulinemia: 2015 update on diagnosis, risk stratification and management. Am Journ of Hematology. 2015;90(4):346–354.
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood. 2014;123:2791–2796.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Federmann B, Schindler N, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;69:795–803.
   Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenström’s macroglobulinemia: an analysis of surveillance, epidemiology and end results database. Blood. 2014;123(25):3999–4000.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Eng J Med. 2002;346:564–569.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010;150(1):28–38.
   PubMed Web of Science ®Google Scholar
• Leleu X, Roccaro AM, Moreau AS, et al. Waldenström’s macroglobulinemia. Cancer Lett. 2008;270:95–107.
   PubMed Web of Science ®Google Scholar
• Gobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenström’s macroglobulinemia. Br J Hematol. 2006;.133:158–164.
   PubMed Web of Science ®Google Scholar
• Ricci F, Tedeschi A, Vismara E, et al. The impact of advanced age according to IPSSWM cut-off on the outcome on symptomatic and asymptomatic Waldenström’s macroglobulinemia at diagnosis. Clin Lymph Myelo Leuk. 2011;11(1):124–126.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Tedeschi A, Arcaini L, et al. Risk of second cancer in Waldenström’s macroglobulinemia. Ann Oncol. 2012;23(2):411–415.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153–161.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45(10):2047–2055.
   PubMed Web of Science ®Google Scholar
• Carney DA, Westerman DA, Tam CS, et al. Therapy related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010;24(12):2056–2062.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126(11):1392–1394.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276–3282.
   PubMed Web of Science ®Google Scholar
• Dimopoulous MA, Chen C, Kastritis E, et al. Bortezomib as treatment options in patients with Waldenstrom’s macroglobulinemia. Clin Lymphoma, Myeloma Leuk. 2010;2:110–117.
   Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol. 2010;85(9):670–674.
   PubMed Web of Science ®Google Scholar
• Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood. 2012;119(10):2205–2208.
   PubMed Web of Science ®Google Scholar
• Stone MJ, Brogen SA. Role of plasmapheresis in Waldenström’s macroglobulinemia. Myelom Leuk. 2013;13(2):238–240.
   PubMed Web of Science ®Google Scholar
• Leblond V, Kastritis E, Advani R, et al. Treatment recommendations for Waldenström’s macroglobulinemia from the Eighth International Workshop on WM. Blood Online July. 2016;128(10):1321–1328.
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68:8384–8392.
   PubMed Web of Science ®Google Scholar
• Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemia. J Immunother. 2001;24(3):272–279.
   Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström’s macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327–2333.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422–1428.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Manning RJ, et al. Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154(3):357–362.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344–3349.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenström’s macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012;118(2):434–443.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Current status of stem cell mobilization. Br J Haematol. 2010;150(6):647–662.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma. 2015;56(9):2637–2642.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830–3835.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood. 2014;124(4):503–510.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Kaufman JL, Raje NS, et al. Updated results from a multicenter, open-label, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with Waldenström macroglobulinemia (WM). Blood. 2014;124:1715.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Trotman J, Tedeschi A, et al. Ibrutinib therapy in rituximab-refractory patients with Waldenström’s macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (INNOVATETM). Blood. 2015;126:Abstract 2745.
   Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 1;31(1):88–94.
   PubMed Web of Science ®Google Scholar
• Gustine J, Meid K, Dubeau TE, et al. Atrial fibrillation associated with ibrutinib in Waldenstrom’s macroglobulinemia. Am J Hematol. 2016;91(6):E312–E313.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;1:133–135.
   Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral m-TOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. Am J Hematol. 2014;89(3):237–242.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2009;15(1):355–360.
   PubMed Web of Science ®Google Scholar
• Gupta IV, Jewell RC. Ofatumumab, the first human anti CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci. 2012;1263:43–56.
   PubMed Web of Science ®Google Scholar
• Buske C, Leblond V, Dimopoulos M, et al. Waldenström’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24((Supplement 6)):155–159.
   Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstrom’s macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160:171–176.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Kyle R, Reeder CB, et al. Diagnosis and management of Waldenstrom’s macroglobulinemia: Mayo stratification of macroglobulinemia and risk- adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85:824–833.
   PubMed Web of Science ®Google Scholar
• Gerzt MA, Reeder CB, Kyle RA, et al. Stem cell transplantation for Waldenstrom’s macroglobulinemia: an underutilized technique. Bone Marrow Transplant. 2011;47:1147–1153.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Boumendi A, Finel H, et al. Autologous stem cell transplantation (ASCT) for the treatment of patients with Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL): a risk factor analysis by the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party. Blood. 2014;124(Abstract):678.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(33):4926–4934.
   PubMed Web of Science ®Google Scholar
• Cheason BD. Ofatumomab, a novel anti-CD20 monoclonal antibody for the treatment of B-malignancies. J Clin Oncol. 2010;28(21):3525–3530.
   PubMed Web of Science ®Google Scholar
• Furman RR, Eradat H, Switzky J, et al. II trial of ofatumumab in subjects with Waldenstrom’s macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2011;118:3701.
   Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Thieblemont C, et al. Efficacy and safety of obinotuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma: results from a phase I/II study (BO20999). Blood (ASH Annual Meeting Abstracts). 2011;118(21):268.
   Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Hunter ZR, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011;118:276–281.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Prospective, multicenter study of the Mtor inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemia. Blood. 2013;122:1822.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Redd R, Armand P, et al. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015;29(12):2338–2346.
   PubMed Web of Science ®Google Scholar
• Fouquet G, Guidez S, Petillon MO, et al. Lenalidomide is safe and active in Waldenstrom macroglobulinemia. Am J Hematol. 2015;90(11):1055–1059.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zomas A, Viniou NA, et al. treatment of Waldenstrom’s macroglobulinemia with thalidomide. J Clin Oncol. 2001;19:3596–3601.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas C, Warren D, et al. Phase I study of pomalidomide, dexamethasone, rituximab (PDR) in patients with Waldenstrom’s macroglobulinemia. Proc. 12th International Conference on Malignant Lymphoma Abstract 536 (2013)
   Google Scholar